Pediatrix Medical Group, Inc. Financials
Pediatrix Medical Group, Inc. (MD) reported $1.9B in revenue for fiscal year 2025, down 4.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business’s dominant mechanic is a profit and cash-flow rebound without top-line growth, alongside reduced leverage.
The FY2025 rebound is operational rather than volume-led: revenue contracted, yet operating margin recovered to10.9% from-3.4% , implying a major shift in costs or mix below gross profit. Cash conversion was also stronger than the income statement suggests: operating cash flow reached$271M versus net income of$165M , so cash generation outpaced reported earnings.
The balance sheet improved at the same time: cash reached
Capital returns totaled
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Pediatrix Medical Group, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Pediatrix Medical Group, Inc. has an operating margin of 10.9%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 47/100, indicating healthy but not exceptional operating efficiency. This is up from -3.4% the prior year.
Pediatrix Medical Group, Inc.'s revenue declined 4.9% year-over-year, from $2.0B to $1.9B. This contraction results in a growth score of 25/100.
Pediatrix Medical Group, Inc. has a moderate D/E ratio of 0.66. This balance of debt and equity financing earns a leverage score of 50/100.
Pediatrix Medical Group, Inc.'s current ratio of 1.66 indicates adequate short-term liquidity, earning a score of 47/100. The company can meet its near-term obligations, though with limited headroom.
Not available for Pediatrix Medical Group, Inc., and counted as zero in the overall score.
Pediatrix Medical Group, Inc.'s ROE of 19.1% shows moderate profitability relative to equity, earning a score of 44/100. This is up from -13.0% the prior year.
Pediatrix Medical Group, Inc. scores 2.21, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Pediatrix Medical Group, Inc. passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Pediatrix Medical Group, Inc. generates $1.64 in operating cash flow ($271.1M OCF vs $165.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Pediatrix Medical Group, Inc. earns $5.81 in operating income for every $1 of interest expense ($208.8M vs $36.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Pediatrix Medical Group, Inc. generated $1.9B in revenue in fiscal year 2025. This represents a decrease of 4.9% from the prior year.
Pediatrix Medical Group, Inc.'s EBITDA was $230.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 732.1% from the prior year.
Pediatrix Medical Group, Inc. reported $165.4M in net income in fiscal year 2025. This represents an increase of 266.9% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Pediatrix Medical Group, Inc. held $375.2M in cash against $570.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Pediatrix Medical Group, Inc.'s operating margin was 10.9% in fiscal year 2025, reflecting core business profitability. This is up 14.3 percentage points from the prior year.
Pediatrix Medical Group, Inc.'s net profit margin was 8.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 13.6 percentage points from the prior year.
Pediatrix Medical Group, Inc.'s ROE was 19.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 32.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Pediatrix Medical Group, Inc. spent $86.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 4990.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
MD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0B | $1.9B-4.9% | $2.0B+0.9% | $2.0B+1.1% | $2.0B+3.2% | $1.9B+10.2% | $1.7B-2.6% | $1.8B+3.3% | $1.7B-47.0% | $3.3B+2.2% | $3.2B | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $248.0M | $240.8M+1.0% | $238.4M+4.8% | $227.5M-1.7% | $231.4M-12.1% | $263.4M+5.8% | $248.9M+1.8% | $244.5M+5.3% | $232.2M-39.8% | $385.9M+3.6% | $372.6M+21.8% | $305.9M+23.6% | $247.5M+13.4% | $218.2M+12.7% | $193.5M+13.6% | $170.4M |
| Operating Income | $215.4M | $208.8M+403.9% | -$68.7M-1038.6% | $7.3M-95.8% | $172.7M-14.9% | $202.9M+106.8% | $98.1M-42.9% | $171.8M-30.9% | $248.4M-45.4% | $454.9M-20.4% | $571.7M+2.5% | $557.9M+8.7% | $513.0M+13.5% | $452.1M+16.1% | $389.5M+9.6% | $355.4M |
| Interest Expense | $34.1M | $36.0M-11.7% | $40.7M-3.2% | $42.1M+6.0% | $39.7M-42.2% | $68.7M-37.8% | $110.5M-7.1% | $118.9M+28.0% | $92.9M+24.7% | $74.6M+18.2% | $63.1M+173.0% | $23.1M+159.9% | $8.9M+64.2% | $5.4M+66.9% | $3.2M-10.8% | $3.6M |
| Income Tax | $51.4M | $51.0M+2346.7% | -$2.3M-118.9% | $12.0M-35.9% | $18.8M-31.0% | $27.2M+62.8% | $16.7M+0.9% | $16.6M-62.9% | $44.7M-44.3% | $80.2M-57.6% | $189.2M-7.3% | $204.0M+6.6% | $191.4M+14.0% | $167.9M+14.0% | $147.3M+8.9% | $135.2M |
| Net Income | $174.8M | $165.4M+266.9% | -$99.1M-64.0% | -$60.4M-191.1% | $66.3M-49.3% | $131.0M+116.4% | -$796.5M+46.8% | -$1.5B-657.5% | $268.6M-16.2% | $320.4M-1.4% | $324.9M-3.4% | $336.3M+6.0% | $317.3M+13.1% | $280.5M+16.4% | $240.9M+10.5% | $218.0M |
| EPS (Diluted) | — | N/A | -$1.19-63.0% | -$0.73-198.6% | $0.74-41.3% | $1.26 | -$0.11-122.0% | $0.50-62.4% | $1.33 | $3.29 | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.2B+4.4% | $2.2B-3.0% | $2.2B-5.5% | $2.3B-13.8% | $2.7B-18.7% | $3.3B-19.2% | $4.1B-30.2% | $5.9B+1.2% | $5.9B+9.9% | $5.3B+17.4% | $4.5B+26.0% | $3.6B+19.9% | $3.0B+9.4% | $2.8B+21.0% | $2.3B |
| Current Assets | $763.5M+19.4% | $639.6M+32.3% | $483.5M+13.0% | $428.0M-49.1% | $840.6M-45.7% | $1.5B+111.8% | $731.5M+10.8% | $660.0M+5.2% | $627.2M+6.8% | $587.1M+11.2% | $527.8M+13.0% | $467.1M+26.9% | $368.1M+2.5% | $359.0M+6.5% | $337.3M |
| Cash & Equivalents | $375.2M+63.2% | $229.9M+213.9% | $73.3M+645.7% | $9.8M-97.5% | $387.4M-65.5% | $1.1B+941.8% | $107.9M+164.6% | $40.8M+0.8% | $40.4M-27.4% | $55.7M+8.0% | $51.6M+7.6% | $47.9M+53.9% | $31.1M+46.3% | $21.3M+14.4% | $18.6M |
| Accounts Receivable | $229.7M-11.7% | $260.0M-4.5% | $272.3M-8.2% | $296.8M-1.7% | $301.8M+24.7% | $241.9M-44.3% | $434.3M-14.3% | $506.7M+0.5% | $504.0M+1.8% | $495.3M+11.4% | $444.7M+26.3% | $352.2M+23.4% | $285.4M+15.0% | $248.1M+7.7% | $230.4M |
| Goodwill | $1.3B+1.5% | $1.2B-10.2% | $1.4B-9.7% | $1.5B+1.8% | $1.5B+1.9% | $1.5B-0.1% | $1.5B-63.6% | $4.1B-5.2% | $4.3B+11.4% | $3.8B+14.2% | $3.4B+21.3% | $2.8B+16.0% | $2.4B+10.5% | $2.2B+24.0% | $1.7B |
| Total Liabilities | $1.4B-0.5% | $1.4B+1.2% | $1.4B-5.9% | $1.5B-20.2% | $1.8B-29.8% | $2.6B-1.8% | $2.6B-7.1% | $2.8B+1.7% | $2.8B+8.6% | $2.6B+22.2% | $2.1B+57.1% | $1.3B+101.7% | $665.7M-6.9% | $715.0M+32.0% | $541.6M |
| Current Liabilities | $458.9M+5.7% | $434.1M+11.6% | $388.9M-8.9% | $427.0M-0.1% | $427.4M-3.8% | $444.3M-18.0% | $541.8M+7.8% | $502.8M-5.4% | $531.4M+18.4% | $448.9M+4.7% | $428.8M+3.0% | $416.3M+27.4% | $326.8M+21.8% | $268.3M+5.5% | $254.3M |
| Long-Term Debt | $570.5M-4.5% | $597.1M-3.4% | $618.4M-2.2% | $632.4M-36.1% | $989.7M-41.8% | $1.7B0.0% | $1.7B-13.7% | $2.0B+6.7% | $1.8B+10.0% | $1.7B+33.2% | $1.3B+126.1% | $557.5M+1964.6% | $27.0M | N/A | N/A |
| Total Equity | $865.9M+13.2% | $764.9M-9.9% | $849.1M-4.8% | $891.6M-0.5% | $896.5M+19.9% | $747.5M-50.1% | $1.5B-51.5% | $3.1B+0.7% | $3.1B+11.1% | $2.8B+13.3% | $2.4B+7.6% | $2.3B-3.3% | $2.3B+15.1% | $2.0B+17.6% | $1.7B |
| Retained Earnings | -$83.2M+66.5% | -$248.5M-66.3% | -$149.5M-67.8% | -$89.1M+42.7% | -$155.4M+45.7% | -$286.4M-156.1% | $510.1M-75.6% | $2.1B+2.3% | $2.0B+14.7% | $1.8B+18.2% | $1.5B+9.7% | $1.4B-7.2% | $1.5B+19.0% | $1.2B+23.9% | $1.0B |
Not reported in any period shown, so not listed: Inventory.
MD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $246.9M | $271.1M+31.2% | $206.6M+50.4% | $137.3M-17.7% | $166.9M+117.5% | $76.7M-62.5% | $204.6M-42.8% | $357.7M+14.0% | $313.7M-38.7% | $511.4M+15.2% | $443.8M+20.4% | $368.7M-12.8% | $422.6M+4.3% | $405.4M+24.8% | $324.9M+20.0% | $270.7M |
| Investing Cash Flow | -$9.6M | -$18.3M+48.3% | -$35.4M+26.5% | -$48.2M+15.4% | -$57.0M-7.3% | -$53.1M-106.5% | $815.5M+696.0% | $102.5M+171.8% | -$142.8M+75.2% | -$576.6M+29.8% | -$821.2M | N/A | N/A | -$263.5M+42.8% | -$460.5M-141.7% | -$190.6M |
| Financing Cash Flow | -$173.1M | -$107.5M-642.1% | -$14.5M+43.7% | -$25.7M+94.7% | -$487.6M+35.9% | -$760.1M-18180.8% | -$4.2M+98.9% | -$393.1M-130.4% | -$170.6M-290.1% | $89.7M-76.5% | $381.6M | N/A | N/A | -$132.1M-195.5% | $138.3M+257.6% | -$87.8M |
| Share Buybacks | $149.1M | $86.7M+4990.0% | $1.7M+85.3% | $919K-99.0% | $88.5M+1775.6% | $4.7M-44.4% | $8.5M-94.2% | $145.3M-51.9% | $302.2M+330.5% | $70.2M+13.5% | $61.8M-73.7% | $235.1M-51.9% | $488.4M+841.8% | $51.9M | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 10.9%+14.3pp | -3.4%-3.8pp | 0.4%-8.4pp | 8.8%-1.9pp | 10.6%+5.0pp | 5.7%-4.0pp | 9.7%-4.8pp | 14.4%+0.4pp | 14.0%-4.0pp | 18.0% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 8.6%+13.6pp | -4.9%-1.9pp | -3.0%-6.4pp | 3.4%-3.5pp | 6.9%+52.8pp | -45.9%+38.2pp | -84.2%-99.7pp | 15.6%+5.7pp | 9.8%-0.4pp | 10.2% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 19.1%+32.0pp | -13.0%-5.8pp | -7.1%-14.5pp | 7.4%-7.2pp | 14.6%+121.2pp | -106.6%-6.7pp | -99.9%-108.6pp | 8.7%-1.8pp | 10.4%-1.3pp | 11.8%-2.0pp | 13.8%-0.2pp | 14.0%+2.0pp | 12.0%+0.1pp | 11.8%-0.8pp | 12.6% |
| Return on Assets | 7.4%+12.0pp | -4.6%-1.9pp | -2.7%-5.5pp | 2.8%-2.0pp | 4.8%+28.6pp | -23.8%+12.3pp | -36.1%-40.6pp | 4.5%-0.9pp | 5.5%-0.6pp | 6.1%-1.3pp | 7.4%-1.4pp | 8.8%-0.5pp | 9.3%+0.6pp | 8.8%-0.8pp | 9.6% |
| Current Ratio | 1.66+0.2x | 1.47+0.2x | 1.24+0.2x | 1.00-1.0x | 1.97-1.5x | 3.49+2.1x | 1.350.0x | 1.31+0.1x | 1.18-0.1x | 1.31+0.1x | 1.23+0.1x | 1.120.0x | 1.13-0.2x | 1.340.0x | 1.33 |
| Debt-to-Equity | 0.66-0.1x | 0.78+0.1x | 0.730.0x | 0.71-0.4x | 1.10-1.2x | 2.27+1.1x | 1.13+0.5x | 0.640.0x | 0.600.0x | 0.61+0.1x | 0.52+0.3x | 0.25+0.2x | 0.01-0.3x | 0.350.0x | 0.31 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Similar Companies
Where Pediatrix Medical Group, Inc. Ranks
Frequently Asked Questions
What is Pediatrix Medical Group, Inc.'s annual revenue?
Pediatrix Medical Group, Inc. (MD) reported $1.9B in total revenue for fiscal year 2025. This represents a -4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Pediatrix Medical Group, Inc.'s revenue growing?
Pediatrix Medical Group, Inc. (MD) revenue declined by 4.9% year-over-year, from $2.0B to $1.9B in fiscal year 2025.
Is Pediatrix Medical Group, Inc. profitable?
Yes, Pediatrix Medical Group, Inc. (MD) reported a net income of $165.4M in fiscal year 2025, with a net profit margin of 8.6%.
What is Pediatrix Medical Group, Inc.'s EBITDA?
Pediatrix Medical Group, Inc. (MD) had EBITDA of $230.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Pediatrix Medical Group, Inc. have?
As of fiscal year 2025, Pediatrix Medical Group, Inc. (MD) had $375.2M in cash and equivalents against $570.5M in long-term debt.
What is Pediatrix Medical Group, Inc.'s operating margin?
Pediatrix Medical Group, Inc. (MD) had an operating margin of 10.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Pediatrix Medical Group, Inc.'s net profit margin?
Pediatrix Medical Group, Inc. (MD) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Pediatrix Medical Group, Inc.'s return on equity (ROE)?
Pediatrix Medical Group, Inc. (MD) has a return on equity of 19.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pediatrix Medical Group, Inc.'s operating cash flow?
Pediatrix Medical Group, Inc. (MD) generated $271.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Pediatrix Medical Group, Inc.'s total assets?
Pediatrix Medical Group, Inc. (MD) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What is Pediatrix Medical Group, Inc.'s current ratio?
Pediatrix Medical Group, Inc. (MD) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.
What is Pediatrix Medical Group, Inc.'s debt-to-equity ratio?
Pediatrix Medical Group, Inc. (MD) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pediatrix Medical Group, Inc.'s return on assets (ROA)?
Pediatrix Medical Group, Inc. (MD) had a return on assets of 7.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pediatrix Medical Group, Inc.'s Altman Z-Score?
Pediatrix Medical Group, Inc. (MD) has an Altman Z-Score of 2.21, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Pediatrix Medical Group, Inc.'s Piotroski F-Score?
Pediatrix Medical Group, Inc. (MD) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pediatrix Medical Group, Inc.'s earnings high quality?
Pediatrix Medical Group, Inc. (MD) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pediatrix Medical Group, Inc. cover its interest payments?
Pediatrix Medical Group, Inc. (MD) has an interest coverage ratio of 5.81x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Pediatrix Medical Group, Inc.?
Pediatrix Medical Group, Inc. (MD) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.